In this article, we look at the 5 best biotech stocks under $10 to buy. If you want to see the full list and how we came up with the list, visit 10 Best Biotech Stocks Under $10 to Buy.

5. Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP)

Number of Hedge Fund Holders: 28 

Stock Price as of Last Close on April 10: $9.80

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) is among the best biotech stocks.

TheFly reported on April 7 that Mizuho raised its price target on CRBP from $39 to $40 while maintaining an Outperform rating. The firm updated its valuation model following the company’s fourth quarter results. The corporation is expected to deliver three clinical data readouts during 2026, which the firm views as key upcoming catalysts. Mizuho also noted that the stock is currently trading near the company’s cash position, suggesting limited downside and an attractive risk-reward profile ahead of multiple potential data-driven events.

Additionally, on April 7, Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) announced it has reached broad alignment with the U.S. FDA on the registration strategy for CRB-701, a next-generation Nectin-4 targeting antibody-drug conjugate being developed for head and neck squamous cell carcinoma and cervical cancer.

The planned registrational approach includes separate randomized controlled studies in each indication comparing CRB-701 to standard chemotherapy regimens, with objective response rate as the basis for potential accelerated approval and overall survival as the confirmatory endpoint for full approval. The company will continue discussions with the FDA to finalize study protocols and statistical analysis plans. In addition, Corbus disclosed a leadership change, with its chief medical officer stepping down effective June 30, 2026.

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) is a clinical-stage biopharmaceutical company focused on developing immunology-based therapies for inflammatory and fibrotic diseases. It is also expanding into oncology, aiming to create targeted treatments that modulate the immune system and improve patient outcomes.

4. ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)

Number of Hedge Fund Holders: 31 

Stock Price as of Last Close on April 10: $8.05

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) is another best biotech stock under $10 to buy.

TheFly reported on April 9 that Northland initiated coverage of SPRY with an Outperform rating and a $25 price target. The firm highlighted Neffy, a needle-free intranasal epinephrine therapy, as a key innovation addressing long-standing challenges associated with injectable epinephrine use. It expects adoption to be supported by both new patient prescriptions and switching from existing injectable treatments, driven by improved ease of use and accessibility.

Linked to that, on March 27, the U.S. FDA approved an update to the prescribing information for neffy 1 mg (epinephrine nasal spray), removing prior age restrictions and allowing use in all patients weighing at least 33 lbs for emergency treatment of type 1 allergic reactions, including anaphylaxis.

The previous requirement limiting use to children aged four and older was eliminated. The revised labeling also provides updated instructions on storage and handling, recommending that patients keep the product in its blister pack or designated carrying case, with the company distributing a free case designed for two devices and planning to include it in future cartons. Additional FDA changes clarified dosing guidance related to accidental sniffing after administration, allowed use after freezing once thawed, and permitted short-term exposure to higher temperatures. The product is available in two strengths, with dosing based on patient weight categories for children and adults.

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) is a biopharmaceutical company focused on developing and commercializing treatments for severe allergic reactions, including an intranasal epinephrine product designed for rapid, needle-free emergency use.

3. Replimune Group, Inc. (NASDAQ:REPL)

Number of Hedge Fund Holders: 34 

Stock Price as of Last Close on April 10: $4.76

Replimune Group, Inc. (NASDAQ:REPL) is among the best biotech stocks to invest in.

TheFly reported on April 13 that Jefferies cut its rating on REPL from Buy to Hold and reduced its price target sharply to $2 from $13. The firm cited increased uncertainty following the FDA’s complete response letter regarding RP1. According to management, further development of RP1 will not proceed unless an accelerated approval pathway is secured within the expected timeframe. Jefferies indicated that the setback creates a more difficult outlook for the program and limits near-term visibility. The firm also noted that the company’s overall development trajectory now appears less clear, with future progress dependent on regulatory outcomes and resolution of current approval concerns.

On April 10, Replimune Group, Inc. (NASDAQ:REPL) stated that the FDA’s complete response letter reflects positions that differ from those communicated in earlier regulatory interactions, particularly the September 2025 Type A meeting. The company noted that a new review team handled the resubmission and did not engage directly despite offers for discussion.

It highlighted that prior agency feedback had supported aspects of the RP1 plus nivolumab dataset, including acknowledgment of challenges in running a randomized control arm and acceptance of certain evidence frameworks. REPL also pointed to earlier regulatory discussions suggesting a single-arm dataset could be sufficient under accelerated approval conditions, contrasting with the later review outcome and concerns raised in the CRL.

Replimune Group, Inc. (NASDAQ:REPL) is a clinical-stage biotechnology company focused on developing oncolytic immunotherapies for cancer. Its proprietary RPx platform is designed to stimulate the immune system to recognize and destroy tumor cells, either alone or in combination with other treatments.

2. Fortrea Holdings Inc. (NASDAQ:FTRE)

Number of Hedge Fund Holders: 35 

Stock Price as of Last Close on April 10: $9.18

Fortrea Holdings Inc. (NASDAQ:FTRE) is among the best biotech stocks.

TheFly reported on April that Evercore ISI cut FTRE price target to $14 from $25 while keeping an Outperform rating. The change was part of a broader Q1 healthcare technology and distribution update, where the firm adjusted models and tactical lists across its coverage. The revision reflects updated near-term assumptions used in its analysis. Despite the lower target, the firm maintained a positive rating on the shares within its sector outlook.

On April 7, Fortrea Holdings Inc. (NASDAQ:FTRE) introduced Fortrea Intelligent Technology (FIT), a new suite of digital and AI-enabled clinical trial solutions aimed at improving efficiency and oversight in study execution. The platform integrates workflow automation, data-driven analytics, and AI-supported tools to enhance decision-making and trial management across sponsors, sites, and internal teams.

FIT expands on FTRE’s existing Xcellerate system and introduces upgraded capabilities across clinical development, clinical pharmacology, and medical device research. The offering is structured around lifecycle tools to speed trial execution, foresight tools for predictive insights, and companion tools designed to improve team productivity. The system is available through full-service and functional service models, with select components offered as SaaS, and is intended to support faster, more reliable, and higher-quality clinical trial delivery.

Fortrea Holdings Inc. (NASDAQ:FTRE) is a global contract research organization (CRO) providing clinical trial management, laboratory services, and drug development support. It helps pharmaceutical, biotech, and medical device companies bring therapies to market through outsourced research and clinical development services.

1. Palisade Bio, Inc. (NASDAQ:PALI)

Number of Hedge Fund Holders: 37 

Stock Price as of Last Close on April 10: $1.82

Palisade Bio, Inc. (NASDAQ:PALI) is among the best biotech stocks to buy under $10.

TheFly reported on April 8 that Wolfe Research initiated coverage of PALI with an Outperform rating and a $7 price target. The firm expects limited near-term activity in 2026 but maintains a constructive long-term view. It points to upcoming ulcerative colitis data expected in the second half of 2027 as a key catalyst, noting that the company’s mechanism and internal analyses support a positive outlook despite mixed results seen in similar drug classes. The firm’s view is based on the potential for the program’s clinical profile to differentiate over time as additional data become available.

Earlier on March 30, Palisade Bio, Inc. (NASDAQ:PALI) reported early-stage results from its Phase 1b study of PALI-2108 in patients with fibrostenotic Crohn’s disease. The oral PDE4 prodrug showed a favorable safety profile with no serious adverse events and only mild, self-limiting side effects. Pharmacokinetic findings supported once-daily dosing with adequate systemic and gut tissue exposure, while pharmacodynamic data showed strong target engagement, including increased cAMP levels in ileal tissue and reductions in inflammatory biomarkers such as fecal calprotectin.

Early signals of clinical benefit were observed, including improvements in endoscopic outcomes and measures of intestinal inflammation. Overall results indicate biologic activity across multiple endpoints and support continued development of PALI-2108 as a potential treatment addressing both inflammation and fibrosis in Crohn’s disease.

Palisade Bio, Inc. (NASDAQ:PALI) is a biopharmaceutical company focused on developing therapeutics for gastrointestinal diseases. Its lead programs target conditions such as acute pancreatitis and other serious GI disorders using protease inhibition and anti-inflammatory approaches.

READ NEXT: 10 Best Mid Cap Stocks to Invest In According to Billionaires and 10 Best Cheap Stocks Under $10 to Buy in April.

Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.